Article info

Original research
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

Authors

  1. Correspondence to Dr Yuanyuan Zhao; zhaoyy{at}sysucc.org.cn; Dr Wenfeng Fang; fangwf{at}sysucc.org.cn
View Full Text

Citation

Yang Y, Zhou T, Chen X, et al
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

Publication history

  • Accepted November 16, 2021
  • First published December 21, 2021.
Online issue publication 
October 25, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.